{"filings":[{"id":92796,"accession_number":"0001193125-26-211922","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q1 net loss $9.1M ($0.54/sh); cash $226.6M; HPI opt-in decision pending mid-2026","event_type":"earnings","confidence":"high","bullets":["Net loss $9.1M ($0.54/share) vs $8.8M ($1.17/share) in Q1 2025; cash $226.6M at quarter end.","Gilead collaboration revenue $8.2M, down from $9.4M YoY; R&D expenses flat at $14.9M.","Completed Phase 1b for ABI-5366/1179 (genital herpes); to decide on 40% U.S. cost-profit share opt-in by mid-2026.","Completed chronic tox for ABI-6250 (HDV entry inhibitor); Phase 2 start expected Q4 2026.","Cash runway projected into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":8213000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103929,"accession_number":"0001193125-26-131872","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Assembly Biosciences adopts 2026 bonus plan; raises CEO bonus target to 65%","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved 2026 Corporate Bonus Plan effective Jan 1, 2026 with corporate and individual performance objectives.","CEO Jason Okazaki's bonus target increased from 60% to 65% of base salary via Amendment No. 1 to employment agreement.","Bonus targets range: CEO up to 75%, other executives 30-55%, non-executives up to 28% of base salary.","Bonuses range from 0 to 1.5 times target; payment expected in Q1 of following year, no later than March 15."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103928,"accession_number":"0001193125-26-115980","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assembly Biosciences reports 2025 revenue of $72.3M; net loss narrows; licenses HPI program to Gilead","event_type":"earnings","confidence":"high","bullets":["Revenue from Gilead collaboration was $72.3M in 2025 (vs $28.5M in 2024); net loss per share $0.55 (vs $6.69).","Cash and marketable securities $248.1M as of Dec 31, 2025, projected to fund operations into 2028.","Licensed helicase-primase inhibitor program (ABI-5366, ABI-1179) to Gilead; received net $35M option fee.","Gilead declined option on ABI-4334 (HBV capsid modulator); Assembly seeking partner for that program.","Phase 2 initiation for ABI-6250 (HDV entry inhibitor) anticipated by end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120200,"accession_number":"0001193125-25-311251","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Assembly Bio reports Phase 1b data: ABI-1179 98% HSV-2 shedding reduction, ABI-5366 monthly 76%","event_type":"other_material","confidence":"high","bullets":["ABI-1179 50 mg weekly: 98% HSV-2 shedding reduction (p<0.01), exceeds 80-85% target; 91% lesion reduction (p<0.01).","ABI-1179: >99% reduction in high viral load shedding, a transmission surrogate.","ABI-5366 monthly dose: 76% HSV-2 shedding reduction (p<0.01), 88% lesion reduction (p=0.01), 81% high viral load reduction.","ABI-5366 weekly 350 mg confirmed: 94% shedding, 97% lesion reduction vs placebo.","Both candidates well-tolerated; Phase 2 planning for ABI-1179 and ABI-5366 weekly; monthly optimization ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120199,"accession_number":"0001193125-25-274235","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assembly Biosciences Q3 net loss $9.2M; cash $232.6M; positive Phase 1b data for ABI-5366","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.2M ($0.72 per share) vs $9.6M loss in Q3 2024; revenue from Gilead collaboration $10.8M.","Cash, cash equivalents and marketable securities $232.6M as of Sep 30, 2025; projected to fund operations into late 2027.","Raised $175M gross proceeds from equity financing with institutional investors in August 2025.","Positive Phase 1b interim data for ABI-5366: significant reductions in HSV-2 shedding and genital lesion rates in recurrent genital herpes.","Phase 1a interim data for ABI-6250 supports progression to Phase 2; additional HSV data (ABI-5366, ABI-1179) expected by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":29834000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136776,"accession_number":"0001193125-25-178092","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Assembly Bio prices $175M equity financing; net proceeds ~$167M","event_type":"other_material","confidence":"high","bullets":["Underwritten offering: 5.6M shares + 1.04M pre-funded warrants at $19.60/unit; net ~$122M.","Gilead purchases 2.3M shares + warrants in private placement at same price; net ~$45M.","Class A warrants exercisable at $21.60, expire 5 years from issuance or 30 days after Phase 2 enrollment announcement.","Class B warrants exercisable after Nov 15, 2026 until Dec 31, 2026; terminate early if $75M non-dilutive collaboration capital received.","Proceeds for general corporate purposes; closings on August 11, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136775,"accession_number":"0001193125-25-176138","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Assembly Bio reports 94% reduction in HSV-2 shedding with ABI-5366 350mg weekly in Phase 1b","event_type":"other_material","confidence":"high","bullets":["94% reduction in HSV-2 shedding rate (p<0.01) for 350mg weekly dose vs placebo over 29-day evaluation.","98% reduction in high viral load shedding (p<0.05) and 94% reduction in genital lesion rate (p<0.01) with 350mg weekly.","ABI-5366 well-tolerated; majority of TEAEs Grade 1-2; no serious adverse events reported.","PK supports weekly and potential monthly dosing; Phase 2 preparation initiated; chronic tox studies complete.","Gilead has opt-in rights to the helicase-primase program; ABI-1179 and monthly cohort data expected fall 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136774,"accession_number":"0000950170-25-104020","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Assembly Bio reports Q2 net loss $10.2M; ABI-6250 shows 4-day half-life supporting once-daily dosing","event_type":"earnings","confidence":"high","bullets":["Net loss $10.2M ($1.33/share) vs $11.2M ($1.98/share) in Q2 2024; revenue from Gilead collaboration $9.6M.","Cash $75.0M as of June 30, 2025, projected to fund operations into mid-2026.","ABI-6250 Phase 1a interim: mean half-life ~4 days supports once-daily oral dosing; dose-dependent bile acid elevations show NTCP target engagement.","Safety: all AEs grade 1-2; one grade 2 ALT elevation at highest single dose (25 mg), self-limited, no serious AEs.","Phase 1b herpes data (ABI-5366, ABI-1179) on track for fall 2025; positive Phase 1b data for ABI-4334 (HBV) reported earlier."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":19045000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153998,"accession_number":"0000950170-25-089949","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Assembly Bio reports positive Phase 1b topline results for ABI-4334 in chronic HBV; Gilead opt-in triggered","event_type":"other_material","confidence":"high","bullets":["Mean HBV DNA decline of 3.2 log10 IU/mL over 28 days in 400 mg cohort (2.9 logs in 150 mg cohort).","Favorable safety: no serious AEs or discontinuations; two grade 3 lab abnormalities resolved with continued dosing.","Half-life supports once-daily oral dosing; exposure at both doses achieved double-digit multiples over target EC50.","Data triggers Gilead's right to opt-in for exclusive license after review of option data package.","ABI-4334 shows potential to inhibit viral replication at 150 mg and cccDNA formation at higher doses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153997,"accession_number":"0000950170-25-083830","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Assembly Biosciences appoints new CFO; shareholders approve stock plan share increases","event_type":"leadership","confidence":"high","bullets":["Jeanette M. Bjorkquist appointed principal financial officer effective June 5, 2025; Jason A. Okazaki remains CEO.","Shareholders approved Amendment No. 1 to 2018 Stock Incentive Plan: shares reserved increased by 375,000 to 1,478,333.","Amendment No. 2 approved: 225,000 additional shares for performance-based vesting retention grants.","ESPP Amendment No. 1 approved: shares reserved increased from 164,500 to 225,000.","All 10 director nominees elected; Ernst & Young ratified as auditor for FY 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}